

# EXECUTIVE SUMMARY

First Nine Months 2024




## Main figures €Mn

<b>Op. Revenue</b> 564.6 (-5%)	<b>EBITDA</b> 167.2 (-2%)	<b>EBIT</b> 146.6 (-4%)
<b>Net profit</b> 113.5 (-4%)	<b>Capex</b> 33.8 (+26%)	<b>Net debt</b> 108.8


**2025 operating revenue guidance:**  
Decrease by a mid-single-digit percentage vs 2024

- ✓ ROVI completes the strategic review of its CDMO business
- ✓ ROVI executes the share capital reduction approved by the 2024 Ordinary General Meeting
- ✓ ROVI announces that Risvan® will not be marketed in the U.S.

## Operating revenue €Mn



## Specialty pharma business €Mn



### Heparin franchise\*

31% of operating revenue

€177.8m -2%

### Other prescription-based pharmaceutical products

**Enoxaparin sales** €101.6m -6%

- ✓ ROVI expects the Q4 to be the strongest quarter of the year in terms of sales, as a higher volume of orders is anticipated.
- ✓ Launched in 40 countries.

**Neparvis®** €38.1m +13%

**Orvatez®** €18.9m -4%

**Bemiparin sales** €71.1m +6%

- ✓ ROVI expects full year sales of Bemiparin to increase by a low-single-digit percentage in 2024 compared to 2023.

**Okedi®** €20.3m +126%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Launched in Europe in 2022 and approved in the U.S., Canada and Australia in 2024.

\* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


## CDMO<sup>(1)</sup> business €Mn

Total  
€253.2m -12%

<sup>(1)</sup> Contract Development and Manufacturing Organisation


To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 39-43) of the press release on the financial results for the first nine months of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

## Gross profit €Mn



■ Gross profit — Gross margin

## SG&A expenses €Mn



■ SG&A — SG&A/Operating revenue

## R&D expenses €Mn €17.4

+5%


Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	<b>Schizophrenia</b>	Approved	Approved in Europe and in the USA, Canada and Australia
Letrozole ISM®, annual	<b>Breast Cancer</b>	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole LEBE, quarterly	<b>Breast Cancer</b>	Phase I	
Risperidone, quarterly	<b>Schizophrenia</b>	Phase I	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 39-43) of the press release on the financial results for the first nine months of 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders/investors/financial-business-information>


## EBITDA €Mn



■ EBITDA — EBITDA Margin

EBITDA Pre-R&D<sup>(1)</sup> €Mn  
 €184.6m -2%

## Net profit €Mn



Net profit Pre-R&D<sup>(1)</sup> €Mn  
 €127.1m -3%

(1) Calculated excluding R&D expenses in 9M 2024 and 9M 2023

## News flow

### SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

### CDMO

- ✓ Evolution of Moderna's vaccine manufacturing
- ✓ Announcement of new contracts
- ✓ Enlarge the production capacities in our plants

### ISM@

### Technology Platform

- ✓ Launch of Okedi® in Europe, Canada, Australia and other countries
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection